1
|
Offensperger F, Tin G, Duran-Frigola M, Hahn E, Dobner S, Ende CWA, Strohbach JW, Rukavina A, Brennsteiner V, Ogilvie K, Marella N, Kladnik K, Ciuffa R, Majmudar JD, Field SD, Bensimon A, Ferrari L, Ferrada E, Ng A, Zhang Z, Degliesposti G, Boeszoermenyi A, Martens S, Stanton R, Müller AC, Hannich JT, Hepworth D, Superti-Furga G, Kubicek S, Schenone M, Winter GE. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells. Science 2024; 384:eadk5864. [PMID: 38662832 DOI: 10.1126/science.adk5864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 03/22/2024] [Indexed: 05/04/2024]
Abstract
Chemical modulation of proteins enables a mechanistic understanding of biology and represents the foundation of most therapeutics. However, despite decades of research, 80% of the human proteome lacks functional ligands. Chemical proteomics has advanced fragment-based ligand discovery toward cellular systems, but throughput limitations have stymied the scalable identification of fragment-protein interactions. We report proteome-wide maps of protein-binding propensity for 407 structurally diverse small-molecule fragments. We verified that identified interactions can be advanced to active chemical probes of E3 ubiquitin ligases, transporters, and kinases. Integrating machine learning binary classifiers further enabled interpretable predictions of fragment behavior in cells. The resulting resource of fragment-protein interactions and predictive models will help to elucidate principles of molecular recognition and expedite ligand discovery efforts for hitherto undrugged proteins.
Collapse
Affiliation(s)
- Fabian Offensperger
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Gary Tin
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Miquel Duran-Frigola
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
- Ersilia Open Source Initiative, Cambridge CB1 3DE, UK
| | - Elisa Hahn
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Sarah Dobner
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | | | | | - Andrea Rukavina
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Vincenth Brennsteiner
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Kevin Ogilvie
- Medicine Design, Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | - Nara Marella
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Katharina Kladnik
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Rodolfo Ciuffa
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | | | | | - Ariel Bensimon
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Luca Ferrari
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna Biocenter 5, 1030 Vienna, Austria
- University of Vienna, Max Perutz Labs, Vienna Biocenter 5, 1030 Vienna, Austria
| | - Evandro Ferrada
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Amanda Ng
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Zhechun Zhang
- Molecular Informatics, Machine Learning and Computational Sciences, Early Clinical Development, Pfizer, Cambridge, MA 02139, USA
| | - Gianluca Degliesposti
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Andras Boeszoermenyi
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Sascha Martens
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna Biocenter 5, 1030 Vienna, Austria
- University of Vienna, Max Perutz Labs, Vienna Biocenter 5, 1030 Vienna, Austria
| | - Robert Stanton
- Molecular Informatics, Machine Learning and Computational Sciences, Early Clinical Development, Pfizer, Cambridge, MA 02139, USA
| | - André C Müller
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - J Thomas Hannich
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | | | - Giulio Superti-Furga
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
- Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
| | - Stefan Kubicek
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | | | - Georg E Winter
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| |
Collapse
|
2
|
Casimiro-Garcia A, Allais C, Brennan A, Choi C, Dower G, Farley KA, Fleming M, Flick A, Frisbie RK, Hall J, Hepworth D, Jones H, Knafels JD, Kortum S, Lovering FE, Mathias JP, Mohan S, Morgan PM, Parng C, Parris K, Pullen N, Schlerman F, Stansfield J, Strohbach JW, Vajdos FF, Vincent F, Wang H, Wang X, Webster R, Wright SW. Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1. J Med Chem 2021; 65:757-784. [PMID: 34967602 DOI: 10.1021/acs.jmedchem.1c01849] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A diaryl ketone series was identified as vanin-1 inhibitors from a high-throughput screening campaign. While this novel scaffold provided valuable probe 2 that was used to build target confidence, concerns over the ketone moiety led to the replacement of this group. The successful replacement of this moiety was achieved with pyrimidine carboxamides derived from cyclic secondary amines that were extensively characterized using biophysical and crystallographic methods as competitive inhibitors of vanin-1. Through optimization of potency and physicochemical and ADME properties, and guided by co-crystal structures with vanin-1, 3 was identified with a suitable profile for advancement into preclinical development.
Collapse
Affiliation(s)
- Agustin Casimiro-Garcia
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Christophe Allais
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Agnes Brennan
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Chulho Choi
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Gabriela Dower
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Kathleen A Farley
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Margaret Fleming
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Andrew Flick
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Richard K Frisbie
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Justin Hall
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - David Hepworth
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Hannah Jones
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - John D Knafels
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Steve Kortum
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Frank E Lovering
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - John P Mathias
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Sashi Mohan
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Paul M Morgan
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Chuenlei Parng
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Kevin Parris
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Nick Pullen
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Franklin Schlerman
- Inflammation and Immunology Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - John Stansfield
- Early Clinical Development Non-Clinical Statistics, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Joseph W Strohbach
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Felix F Vajdos
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Fabien Vincent
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Hong Wang
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Xiaolun Wang
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Robert Webster
- Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Stephen W Wright
- Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States
| |
Collapse
|
3
|
Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gürtl B, Klavins K, Klimek C, Lindinger S, Liñeiro-Retes E, Müller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, Hepworth D, Liu S, Noell S, Piotrowski M, Stanton R, Zhang H, Corallino S, Faedo A, Insidioso M, Maresca G, Redaelli L, Sassone F, Scarabottolo L, Stucchi M, Tarroni P, Tremolada S, Batoulis H, Becker A, Bender E, Chang YN, Ehrmann A, Müller-Fahrnow A, Pütter V, Zindel D, Hamilton B, Lenter M, Santacruz D, Viollet C, Whitehurst C, Johnsson K, Leippe P, Baumgarten B, Chang L, Ibig Y, Pfeifer M, Reinhardt J, Schönbett J, Selzer P, Seuwen K, Bettembourg C, Biton B, Czech J, de Foucauld H, Didier M, Licher T, Mikol V, Pommereau A, Puech F, Yaligara V, Edwards A, Bongers BJ, Heitman LH, IJzerman AP, Sijben HJ, van Westen GJ, Grixti J, Kell DB, Mughal F, Swainston N, Wright-Muelas M, Bohstedt T, Burgess-Brown N, Carpenter L, Dürr K, Hansen J, Scacioc A, Banci G, Colas C, Digles D, Ecker G, Füzi B, Gamsjäger V, Grandits M, Martini R, Troger F, Altermatt P, Doucerain C, Dürrenberger F, Manolova V, Steck AL, Sundström H, Wilhelm M, Steppan CM. The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Nat Rev Drug Discov 2020; 19:429-430. [DOI: 10.1038/d41573-020-00056-6] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
4
|
Sinitsyna OV, Makarov VV, McGeachy K, Bukharova T, Whale E, Hepworth D, Yaminsky IV, Kalinina NO, Taliansky ME, Love AJ. Virus-Like Particle Facilitated Deposition of Hydroxyapatite Bone Mineral on Nanocellulose after Exposure to Phosphate and Calcium Precursors. Int J Mol Sci 2019; 20:E1814. [PMID: 31013736 PMCID: PMC6515374 DOI: 10.3390/ijms20081814] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 04/04/2019] [Accepted: 04/09/2019] [Indexed: 11/28/2022] Open
Abstract
We produced and isolated tobacco mosaic virus-like particles (TMV VLPs) from bacteria, which are devoid of infectious genomes, and found that they have a net negative charge and can bind calcium ions. Moreover, we showed that the TMV VLPs could associate strongly with nanocellulose slurry after a simple mixing step. We sequentially exposed nanocellulose alone or slurries mixed with the TMV VLPs to calcium and phosphate salts and utilized physicochemical approaches to demonstrate that bone mineral (hydroxyapatite) was deposited only in nanocellulose mixed with the TMV VLPs. The TMV VLPs confer mineralization properties to the nanocellulose for the generation of new composite materials.
Collapse
Affiliation(s)
- Olga V Sinitsyna
- A.N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences, Moscow 119991, Russia.
| | - Valentine V Makarov
- A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 119991, Russia.
| | - Kara McGeachy
- Cell and Molecular Sciences, The James Hutton Institute, Dundee DD2 5DA, UK.
| | - Tatyana Bukharova
- Cell and Molecular Sciences, The James Hutton Institute, Dundee DD2 5DA, UK.
| | - Eric Whale
- CelluComp Ltd., Unit 3, West Dock, Harbour Place, Burntisland KY3 9DW, UK.
| | - David Hepworth
- CelluComp Ltd., Unit 3, West Dock, Harbour Place, Burntisland KY3 9DW, UK.
| | - Igor V Yaminsky
- Physical Faculty, Lomonosov Moscow State University, Moscow 119991, Russia.
| | - Natalia O Kalinina
- A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow 119991, Russia.
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 119991, Russia.
| | - Michael E Taliansky
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 119991, Russia.
- Cell and Molecular Sciences, The James Hutton Institute, Dundee DD2 5DA, UK.
| | - Andrew J Love
- Cell and Molecular Sciences, The James Hutton Institute, Dundee DD2 5DA, UK.
| |
Collapse
|
5
|
Holland C, Perzon A, Cassland PRC, Jensen JP, Langebeck B, Sørensen OB, Whale E, Hepworth D, Plaice-Inglis R, Moestrup Ø, Ulvskov P, Jørgensen B. Nanofibers Produced from Agro-Industrial Plant Waste Using Entirely Enzymatic Pretreatments. Biomacromolecules 2018; 20:443-453. [DOI: 10.1021/acs.biomac.8b01435] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Claire Holland
- Department of Plant and Environmental Sciences, Section for Glycobiology, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark
| | - Alixander Perzon
- Department of Plant and Environmental Sciences, Section for Glycobiology, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark
| | | | - John P. Jensen
- Nordzucker, Technology and Innovation, Falckvænget 1, 4900 Nakskov, Denmark
| | - Birger Langebeck
- Nordzucker, Technology and Innovation, Falckvænget 1, 4900 Nakskov, Denmark
| | | | - Eric Whale
- Cellucomp Ltd., Unit 3, West
Dock, Harbour Place, Burntisland, Fife KY3 9DW, United Kingdom
| | - David Hepworth
- Cellucomp Ltd., Unit 3, West
Dock, Harbour Place, Burntisland, Fife KY3 9DW, United Kingdom
| | - Robyn Plaice-Inglis
- Cellucomp Ltd., Unit 3, West
Dock, Harbour Place, Burntisland, Fife KY3 9DW, United Kingdom
| | - Øjvind Moestrup
- Department of Biology, University of Copenhagen, 2100 København Ø, Denmark
| | - Peter Ulvskov
- Department of Plant and Environmental Sciences, Section for Glycobiology, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark
| | - Bodil Jørgensen
- Department of Plant and Environmental Sciences, Section for Glycobiology, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark
| |
Collapse
|
6
|
Hall J, Brault A, Vincent F, Weng S, Wang H, Dumlao D, Aulabaugh A, Aivazian D, Castro D, Chen M, Culp J, Dower K, Gardner J, Hawrylik S, Golenbock D, Hepworth D, Horn M, Jones L, Jones P, Latz E, Li J, Lin LL, Lin W, Lin D, Lovering F, Niljanskul N, Nistler R, Pierce B, Plotnikova O, Schmitt D, Shanker S, Smith J, Snyder W, Subashi T, Trujillo J, Tyminski E, Wang G, Wong J, Lefker B, Dakin L, Leach K. Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay. PLoS One 2017; 12:e0184843. [PMID: 28934246 PMCID: PMC5608272 DOI: 10.1371/journal.pone.0184843] [Citation(s) in RCA: 91] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 08/31/2017] [Indexed: 12/30/2022] Open
Abstract
Cyclic GMP-AMP synthase (cGAS) initiates the innate immune system in response to cytosolic dsDNA. After binding and activation from dsDNA, cGAS uses ATP and GTP to synthesize 2', 3' -cGAMP (cGAMP), a cyclic dinucleotide second messenger with mixed 2'-5' and 3'-5' phosphodiester bonds. Inappropriate stimulation of cGAS has been implicated in autoimmune disease such as systemic lupus erythematosus, thus inhibition of cGAS may be of therapeutic benefit in some diseases; however, the size and polarity of the cGAS active site makes it a challenging target for the development of conventional substrate-competitive inhibitors. We report here the development of a high affinity (KD = 200 nM) inhibitor from a low affinity fragment hit with supporting biochemical and structural data showing these molecules bind to the cGAS active site. We also report a new high throughput cGAS fluorescence polarization (FP)-based assay to enable the rapid identification and optimization of cGAS inhibitors. This FP assay uses Cy5-labelled cGAMP in combination with a novel high affinity monoclonal antibody that specifically recognizes cGAMP with no cross reactivity to cAMP, cGMP, ATP, or GTP. Given its role in the innate immune response, cGAS is a promising therapeutic target for autoinflammatory disease. Our results demonstrate its druggability, provide a high affinity tool compound, and establish a high throughput assay for the identification of next generation cGAS inhibitors.
Collapse
Affiliation(s)
- Justin Hall
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Amy Brault
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Fabien Vincent
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Shawn Weng
- Pfizer Centers for Therapeutic Innovation (CTI), Boston, Massachusetts, United States of America
| | - Hong Wang
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Darren Dumlao
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Ann Aulabaugh
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Dikran Aivazian
- Pfizer Centers for Therapeutic Innovation (CTI), San Diego, California, United States of America
| | - Dana Castro
- Pfizer Centers for Therapeutic Innovation (CTI), San Diego, California, United States of America
| | - Ming Chen
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Jeffrey Culp
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Ken Dower
- Inflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America
| | - Joseph Gardner
- External Research Solutions, Pfizer, Groton, Connecticut, United States of America
| | - Steven Hawrylik
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Douglas Golenbock
- University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - David Hepworth
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | - Mark Horn
- Pfizer Centers for Therapeutic Innovation (CTI), San Diego, California, United States of America
| | - Lyn Jones
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | - Peter Jones
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | - Eicke Latz
- University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
- Institute of Innate Immunity, University Hospitals Bonn, Bonn, Germany
| | - Jing Li
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | - Lih-Ling Lin
- Inflammation and Immunology, Pfizer, Cambridge, Massachusetts, United States of America
| | - Wen Lin
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - David Lin
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Frank Lovering
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | | | - Ryan Nistler
- Pfizer Centers for Therapeutic Innovation (CTI), Boston, Massachusetts, United States of America
| | - Betsy Pierce
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Olga Plotnikova
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Daniel Schmitt
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Suman Shanker
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - James Smith
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - William Snyder
- Pfizer Centers for Therapeutic Innovation (CTI), San Diego, California, United States of America
| | - Timothy Subashi
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - John Trujillo
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Edyta Tyminski
- Pfizer Centers for Therapeutic Innovation (CTI), Boston, Massachusetts, United States of America
| | - Guoxing Wang
- Pfizer Centers for Therapeutic Innovation (CTI), Boston, Massachusetts, United States of America
| | - Jimson Wong
- Medicine Design, Pfizer, Groton, Connecticut, United States of America
| | - Bruce Lefker
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | - Leslie Dakin
- Medicine Design, Pfizer, Cambridge, Massachusetts, United States of America
| | - Karen Leach
- Pfizer Centers for Therapeutic Innovation (CTI), Boston, Massachusetts, United States of America
| |
Collapse
|
7
|
Lee KL, Ambler CM, Anderson DR, Boscoe BP, Bree AG, Brodfuehrer JI, Chang JS, Choi C, Chung S, Curran KJ, Day JE, Dehnhardt CM, Dower K, Drozda SE, Frisbie RK, Gavrin LK, Goldberg JA, Han S, Hegen M, Hepworth D, Hope HR, Kamtekar S, Kilty IC, Lee A, Lin LL, Lovering FE, Lowe MD, Mathias JP, Morgan HM, Murphy EA, Papaioannou N, Patny A, Pierce BS, Rao VR, Saiah E, Samardjiev IJ, Samas BM, Shen MWH, Shin JH, Soutter HH, Strohbach JW, Symanowicz PT, Thomason JR, Trzupek JD, Vargas R, Vincent F, Yan J, Zapf CW, Wright SW. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem 2017; 60:5521-5542. [PMID: 28498658 DOI: 10.1021/acs.jmedchem.7b00231] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays. The medicinal chemistry effort featured the judicious placement of lipophilicity, informed by co-crystal structures with IRAK4 and optimization of ADME properties to deliver clinical candidate PF-06650833 (compound 40). This compound displays a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Heidi M Morgan
- Worldwide Medicinal Chemistry, Pfizer Inc. , 1070 Science Center Drive, San Diego, California 92121, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jiangli Yan
- Worldwide Medicinal Chemistry, Pfizer Inc. , 1070 Science Center Drive, San Diego, California 92121, United States
| | | | | |
Collapse
|
8
|
Futatsugi K, Huard K, Kung DW, Pettersen JC, Flynn DA, Gosset JR, Aspnes GE, Barnes RJ, Cabral S, Dowling MS, Fernando DP, Goosen TC, Gorczyca WP, Hepworth D, Herr M, Lavergne S, Li Q, Niosi M, Orr STM, Pardo ID, Perez SM, Purkal J, Schmahai TJ, Shirai N, Shoieb AM, Zhou J, Goodwin B. Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile. Medchemcomm 2016; 8:771-779. [PMID: 30108796 DOI: 10.1039/c6md00564k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 11/08/2016] [Indexed: 11/21/2022]
Abstract
Small molecule DGAT2 inhibitors have shown promise for the treatment of metabolic diseases in preclinical models. Herein, we report the first toxicological evaluation of imidazopyridine-based DGAT2 inhibitors and show that the arteriopathy associated with imidazopyridine 1 can be mitigated with small structural modifications, and is thus not mechanism related.
Collapse
Affiliation(s)
- K Futatsugi
- Pfizer Inc. Medicine Design , 610 Main Street , Cambridge , Massachusetts , 02155 USA .
| | - K Huard
- Pfizer Inc. Medicine Design , 610 Main Street , Cambridge , Massachusetts , 02155 USA .
| | - D W Kung
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - J C Pettersen
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - D A Flynn
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - J R Gosset
- Pfizer Inc. Medicine Design , 610 Main Street , Cambridge , Massachusetts , 02155 USA .
| | - G E Aspnes
- Pfizer Inc. Medicine Design , 610 Main Street , Cambridge , Massachusetts , 02155 USA .
| | - R J Barnes
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - S Cabral
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - M S Dowling
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - D P Fernando
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - T C Goosen
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - W P Gorczyca
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - D Hepworth
- Pfizer Inc. Medicine Design , 610 Main Street , Cambridge , Massachusetts , 02155 USA .
| | - M Herr
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - S Lavergne
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - Q Li
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - M Niosi
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - S T M Orr
- Pfizer Inc. Medicine Design , Eastern Point Road , Groton , Connecticut , 06340 USA .
| | - I D Pardo
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - S M Perez
- Pfizer Inc. Cardiovascular and Metabolic Disease Research Unit , 610 Main Street , Cambridge , Massachusetts , 02155 USA
| | - J Purkal
- Pfizer Inc. Cardiovascular and Metabolic Disease Research Unit , 610 Main Street , Cambridge , Massachusetts , 02155 USA
| | - T J Schmahai
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - N Shirai
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - A M Shoieb
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - J Zhou
- Pfizer Inc. Drug Safety Research and Development , Eastern Point Road , Groton , Connecticut , 06340 USA
| | - B Goodwin
- Pfizer Inc. Cardiovascular and Metabolic Disease Research Unit , 610 Main Street , Cambridge , Massachusetts , 02155 USA
| |
Collapse
|
9
|
Cameron KO, Kung DW, Kalgutkar AS, Kurumbail RG, Miller R, Salatto CT, Ward J, Withka JM, Bhattacharya SK, Boehm M, Borzilleri KA, Brown JA, Calabrese M, Caspers NL, Cokorinos E, Conn EL, Dowling MS, Edmonds DJ, Eng H, Fernando DP, Frisbie R, Hepworth D, Landro J, Mao Y, Rajamohan F, Reyes AR, Rose CR, Ryder T, Shavnya A, Smith AC, Tu M, Wolford AC, Xiao J. Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy. J Med Chem 2016; 59:8068-81. [DOI: 10.1021/acs.jmedchem.6b00866] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Kimberly O. Cameron
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Daniel W. Kung
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Ravi G. Kurumbail
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Russell Miller
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Christopher T. Salatto
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jessica Ward
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jane M. Withka
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Samit K. Bhattacharya
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kris A. Borzilleri
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Janice A. Brown
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Matthew Calabrese
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Nicole L. Caspers
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Emily Cokorinos
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Edward L. Conn
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Matthew S. Dowling
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - David J. Edmonds
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Heather Eng
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Dilinie P. Fernando
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Richard Frisbie
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - David Hepworth
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - James Landro
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Yuxia Mao
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Francis Rajamohan
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Allan R. Reyes
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Colin R. Rose
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Tim Ryder
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Andre Shavnya
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Aaron C. Smith
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Meihua Tu
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Angela C. Wolford
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jun Xiao
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
- Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Worldwide Medicinal Chemistry, ∇Pharmacokinetics, Dynamics and Metabolism, ○Pharmaceutical Sciences, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| |
Collapse
|
10
|
Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L, Wang S, Guzova J, Jiao A, Lin LL, Latz E, Hepworth D, Hall JP. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation. J I 2016; 197:2421-33. [DOI: 10.4049/jimmunol.1600035] [Citation(s) in RCA: 103] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Accepted: 07/12/2016] [Indexed: 01/12/2023]
|
11
|
Huard K, Brown J, Jones JC, Cabral S, Futatsugi K, Gorgoglione M, Lanba A, Vera NB, Zhu Y, Yan Q, Zhou Y, Vernochet C, Riccardi K, Wolford A, Pirman D, Niosi M, Aspnes G, Herr M, Genung NE, Magee TV, Uccello DP, Loria P, Di L, Gosset JR, Hepworth D, Rolph T, Pfefferkorn JA, Erion DM. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). Sci Rep 2015; 5:17391. [PMID: 26620127 PMCID: PMC4664966 DOI: 10.1038/srep17391] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Accepted: 10/29/2015] [Indexed: 12/13/2022] Open
Abstract
Citrate is a key regulatory metabolic intermediate as it facilitates the integration of the glycolysis and lipid synthesis pathways. Inhibition of hepatic extracellular citrate uptake, by blocking the sodium-coupled citrate transporter (NaCT or SLC13A5), has been suggested as a potential therapeutic approach to treat metabolic disorders. NaCT transports citrate from the blood into the cell coupled to the transport of sodium ions. The studies herein report the identification and characterization of a novel small dicarboxylate molecule (compound 2) capable of selectively and potently inhibiting citrate transport through NaCT, both in vitro and in vivo. Binding and transport experiments indicate that 2 specifically binds NaCT in a competitive and stereosensitive manner, and is recognized as a substrate for transport by NaCT. The favorable pharmacokinetic properties of 2 permitted in vivo experiments to evaluate the effect of inhibiting hepatic citrate uptake on metabolic endpoints.
Collapse
Affiliation(s)
- Kim Huard
- Worldwide Medicinal Chemistry, 610 Main street, Cambridge, MA 02139
| | - Janice Brown
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - Jessica C Jones
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Shawn Cabral
- Worldwide Medicinal Chemistry, Eastern Point road, Groton, CT 06340
| | | | - Matthew Gorgoglione
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Adhiraj Lanba
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Nicholas B Vera
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Yimin Zhu
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Qingyun Yan
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Yingjiang Zhou
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Cecile Vernochet
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Keith Riccardi
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - Angela Wolford
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - David Pirman
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - Mark Niosi
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - Gary Aspnes
- Worldwide Medicinal Chemistry, 610 Main street, Cambridge, MA 02139
| | - Michael Herr
- Worldwide Medicinal Chemistry, Eastern Point road, Groton, CT 06340
| | - Nathan E Genung
- Worldwide Medicinal Chemistry, Eastern Point road, Groton, CT 06340
| | - Thomas V Magee
- Worldwide Medicinal Chemistry, 610 Main street, Cambridge, MA 02139
| | - Daniel P Uccello
- Worldwide Medicinal Chemistry, Eastern Point road, Groton, CT 06340
| | - Paula Loria
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - Li Di
- Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340
| | - James R Gosset
- Pharmacokinetics, Dynamics, and Metabolism, 610 Main street, Cambridge, MA 02139
| | - David Hepworth
- Worldwide Medicinal Chemistry, 610 Main street, Cambridge, MA 02139
| | - Timothy Rolph
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Jeffrey A Pfefferkorn
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| | - Derek M Erion
- Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139
| |
Collapse
|
12
|
Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, Ford K, Guimarães CRW, Hepworth D, Jiao W, LaPerle J, Liu S, Londregan A, Loria PM, Mathiowetz AM, Munchhof M, Orr STM, Petersen DN, Price DA, Skoura A, Smith AC, Wang J. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Med Chem Lett 2015; 6:1128-33. [PMID: 26617966 DOI: 10.1021/acsmedchemlett.5b00215] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 09/28/2015] [Indexed: 01/12/2023] Open
Abstract
Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of concept in vivo. The medicinal chemistry effort that led to the discovery of these lead compounds is described herein together with in vivo pharmacokinetic properties and activity in a model of insulin resistance.
Collapse
Affiliation(s)
- Mark Ammirati
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Scott W. Bagley
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Samit K. Bhattacharya
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Leonard Buckbinder
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Anthony A. Carlo
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Rebecca Conrad
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Christian Cortes
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Robert L. Dow
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Matthew S. Dowling
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Ayman El-Kattan
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Kristen Ford
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Cristiano R. W. Guimarães
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Wenhua Jiao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Jennifer LaPerle
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Shenping Liu
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Allyn Londregan
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Paula M. Loria
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Alan M. Mathiowetz
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Michael Munchhof
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Suvi T. M. Orr
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Donna N. Petersen
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - David A. Price
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Athanasia Skoura
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Aaron C. Smith
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Jian Wang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and Metabolic Research Unit, §External Research Solutions, ∥Primary Pharmacology Group, and ⊥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
13
|
Ruggeri RB, Buckbinder L, Bagley SW, Carpino PA, Conn EL, Dowling MS, Fernando DP, Jiao W, Kung DW, Orr STM, Qi Y, Rocke BN, Smith A, Warmus JS, Zhang Y, Bowles D, Widlicka DW, Eng H, Ryder T, Sharma R, Wolford A, Okerberg C, Walters K, Maurer TS, Zhang Y, Bonin PD, Spath SN, Xing G, Hepworth D, Ahn K, Kalgutkar AS. Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. J Med Chem 2015; 58:8513-28. [DOI: 10.1021/acs.jmedchem.5b00963] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Roger B. Ruggeri
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Leonard Buckbinder
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Scott W. Bagley
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Philip A. Carpino
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Edward L. Conn
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Matthew S. Dowling
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Dilinie P. Fernando
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Daniel W. Kung
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Suvi T. M. Orr
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Yingmei Qi
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Benjamin N. Rocke
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Aaron Smith
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Joseph S. Warmus
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Yan Zhang
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Daniel Bowles
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Daniel W. Widlicka
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Heather Eng
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Tim Ryder
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Raman Sharma
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Angela Wolford
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Carlin Okerberg
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Karen Walters
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Tristan S. Maurer
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Yanwei Zhang
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Paul D. Bonin
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Samantha N. Spath
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Gang Xing
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - David Hepworth
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Kay Ahn
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Worldwide Research
and Development, Pfizer,
Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
14
|
César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, Superti-Furga G. A Call for Systematic Research on Solute Carriers. Cell 2015; 162:478-87. [PMID: 26232220 DOI: 10.1016/j.cell.2015.07.022] [Citation(s) in RCA: 362] [Impact Index Per Article: 40.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Indexed: 01/10/2023]
Abstract
Solute carrier (SLC) membrane transport proteins control essential physiological functions, including nutrient uptake, ion transport, and waste removal. SLCs interact with several important drugs, and a quarter of the more than 400 SLC genes are associated with human diseases. Yet, compared to other gene families of similar stature, SLCs are relatively understudied. The time is right for a systematic attack on SLC structure, specificity, and function, taking into account kinship and expression, as well as the dependencies that arise from the common metabolic space.
Collapse
Affiliation(s)
- Adrián César-Razquin
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Berend Snijder
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | | | - Ruth Isserlin
- The Donnelly Centre, University of Toronto, Toronto, Ontario, M5S 3E1, Canada
| | - Gergely Gyimesi
- Institute of Biochemistry and Molecular Medicine and Swiss National Center of Competence in Research, NCCR TransCure, University of Bern, 3012 Bern, Switzerland
| | - Xiaoyun Bai
- Department of Biochemistry, University of Toronto, Toronto, Ontario, M5S 1A8 Canada
| | | | - David Hepworth
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | - Matthias A Hediger
- Institute of Biochemistry and Molecular Medicine and Swiss National Center of Competence in Research, NCCR TransCure, University of Bern, 3012 Bern, Switzerland.
| | - Aled M Edwards
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
| | - Giulio Superti-Furga
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
| |
Collapse
|
15
|
Futatsugi K, Kung DW, Orr STM, Cabral S, Hepworth D, Aspnes G, Bader S, Bian J, Boehm M, Carpino PA, Coffey SB, Dowling MS, Herr M, Jiao W, Lavergne SY, Li Q, Clark RW, Erion DM, Kou K, Lee K, Pabst BA, Perez SM, Purkal J, Jorgensen CC, Goosen TC, Gosset JR, Niosi M, Pettersen JC, Pfefferkorn JA, Ahn K, Goodwin B. Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). J Med Chem 2015; 58:7173-85. [DOI: 10.1021/acs.jmedchem.5b01006] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Kentaro Futatsugi
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Daniel W. Kung
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Suvi T. M. Orr
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Shawn Cabral
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Gary Aspnes
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Scott Bader
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jianwei Bian
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Philip A. Carpino
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Steven B. Coffey
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Matthew S. Dowling
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Michael Herr
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Sophie Y. Lavergne
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Qifang Li
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Ronald W. Clark
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Derek M. Erion
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kou Kou
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kyuha Lee
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Brandon A. Pabst
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Sylvie M. Perez
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Julie Purkal
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Csilla C. Jorgensen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Theunis C. Goosen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - James R. Gosset
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Mark Niosi
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - John C. Pettersen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Jeffrey A. Pfefferkorn
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kay Ahn
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Bryan Goodwin
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
- Worldwide Medicinal Chemistry, ⊥Cardiovascular, Metabolic and Endocrine Diseases Research Unit, #Pharmacokinetics, Dynamics and Metabolism, ∇Pharmaceutical Sciences, and ○Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| |
Collapse
|
16
|
Huard K, Londregan AT, Tesz G, Bahnck KB, Magee TV, Hepworth D, Polivkova J, Coffey SB, Pabst BA, Gosset JR, Nigam A, Kou K, Sun H, Lee K, Herr M, Boehm M, Carpino PA, Goodwin B, Perreault C, Li Q, Jorgensen CC, Tkalcevic GT, Subashi TA, Ahn K. Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3. J Med Chem 2015; 58:7164-72. [PMID: 26258602 DOI: 10.1021/acs.jmedchem.5b01008] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Inhibition of triacylglycerol (TAG) biosynthetic enzymes has been suggested as a promising strategy to treat insulin resistance, diabetes, dyslipidemia, and hepatic steatosis. Monoacylglycerol acyltransferase 3 (MGAT3) is an integral membrane enzyme that catalyzes the acylation of both monoacylglycerol (MAG) and diacylglycerol (DAG) to generate DAG and TAG, respectively. Herein, we report the discovery and characterization of the first selective small molecule inhibitors of MGAT3. Isoindoline-5-sulfonamide (6f, PF-06471553) selectively inhibits MGAT3 with high in vitro potency and cell efficacy. Because the gene encoding MGAT3 (MOGAT3) is found only in higher mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOGAT3 was used to characterize the effects of 6f in vivo. In the presence of a combination of diacylglycerol acyltransferases 1 and 2 (DGAT1 and DGAT2) inhibitors, an oral administration of 6f exhibited inhibition of the incorporation of deuterium-labeled glycerol into TAG in this mouse model. The availability of a potent and selective chemical tool and a humanized mouse model described in this report should facilitate further dissection of the physiological function of MGAT3 and its role in lipid homeostasis.
Collapse
Affiliation(s)
- Kim Huard
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Allyn T Londregan
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Gregory Tesz
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Kevin B Bahnck
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Thomas V Magee
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Jana Polivkova
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Steven B Coffey
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Brandon A Pabst
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - James R Gosset
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Anu Nigam
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Kou Kou
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Hao Sun
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Kyuha Lee
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Michael Herr
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Markus Boehm
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Philip A Carpino
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Bryan Goodwin
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Christian Perreault
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Qifang Li
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Csilla C Jorgensen
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - George T Tkalcevic
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Timothy A Subashi
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| | - Kay Ahn
- Worldwide Medicinal Chemistry, ‡Cardiovascular, Metabolic and Endocrine Diseases Research Unit, and §Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Cambridge, Massachusetts 02139, United States.,Worldwide Medicinal Chemistry, ∥Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development , Groton, Connecticut 06340, United States
| |
Collapse
|
17
|
Orr STM, Beveridge R, Bhattacharya SK, Cameron KO, Coffey S, Fernando D, Hepworth D, Jackson MV, Khot V, Kosa R, Lapham K, Loria PM, McClure KF, Patel J, Rose C, Saenz J, Stock IA, Storer G, von Volkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y. Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists. ACS Med Chem Lett 2015; 6:156-61. [PMID: 25699143 DOI: 10.1021/ml500414n] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 12/14/2014] [Indexed: 01/16/2023] Open
Abstract
Several polar heteroaromatic acetic acids and their piperidine amides were synthesized and evaluated as ghrelin or type 1a growth hormone secretagogue receptor (GHS-R1a) inverse agonists. Efforts to improve pharmacokinetic and safety profile was achieved by modulating physicochemical properties and, more specifically, emphasizing increased polarity of our chemical series. ortho-Carboxamide containing compounds provided optimal physicochemical, pharmacologic, and safety profile. pH-dependent chemical stability was also assessed with our series.
Collapse
Affiliation(s)
- Suvi T. M. Orr
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 10770
Science Center Drive, San Diego, California 92121, United States
| | - Ramsay Beveridge
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Samit K. Bhattacharya
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 610
Main St., Cambridge, Massachusetts 02139, United States
| | - Kimberly O. Cameron
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 610
Main St., Cambridge, Massachusetts 02139, United States
| | - Steven Coffey
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Dilinie Fernando
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - David Hepworth
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 610
Main St., Cambridge, Massachusetts 02139, United States
| | - Margaret V. Jackson
- Cardiovascular
and Metabolic Research Unit, Pfizer Global Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Vishal Khot
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Rachel Kosa
- Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kimberly Lapham
- Pharmacokinetics,
Dynamics and Metabolism, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paula M. Loria
- Primary
Pharmacology Group, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kim F. McClure
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 610
Main St., Cambridge, Massachusetts 02139, United States
| | - Jigna Patel
- Pharmaceutical
Sciences, Pfizer Global Research and Development, 550 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Colin Rose
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 610
Main St., Cambridge, Massachusetts 02139, United States
| | - James Saenz
- Pharmaceutical
Sciences, Pfizer Global Research and Development, 550 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ingrid A. Stock
- Primary
Pharmacology Group, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gregory Storer
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Maria von Volkenburg
- Cardiovascular
and Metabolic Research Unit, Pfizer Global Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Derek Vrieze
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Guoqiang Wang
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jun Xiao
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| | - Yingxin Zhang
- Worldwide
Medicinal Chemistry, Pfizer Global Research and Development, 550
Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
18
|
Nolte WM, Fortin JP, Stevens BD, Aspnes GE, Griffith DA, Hoth LR, Ruggeri RB, Mathiowetz AM, Limberakis C, Hepworth D, Carpino PA. A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat Chem Biol 2014; 10:629-31. [PMID: 24997604 DOI: 10.1038/nchembio.1581] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Accepted: 06/10/2014] [Indexed: 02/06/2023]
Abstract
We report that 4-(3-(benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), which behaves as a positive allosteric modulator at the glucagon-like peptide-1 receptor (GLP-1R), covalently modifies cysteines 347 and 438 in GLP-1R. C347, located in intracellular loop 3 of GLP-1R, is critical to the activity of BETP and a structurally distinct GLP-1R ago-allosteric modulator, N-(tert-butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine. We further show that substitution of cysteine for phenylalanine 345 in the glucagon receptor is sufficient to confer sensitivity to BETP.
Collapse
Affiliation(s)
- Whitney M Nolte
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Jean-Philippe Fortin
- Cardiovascular and Metabolic Diseases Research Unit, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Benjamin D Stevens
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Gary E Aspnes
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Groton, Connecticut, USA
| | - David A Griffith
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Lise R Hoth
- Structural Biology and Biophysics Group, Center for Chemistry Innovation and Excellence, Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Groton, Connecticut, USA
| | - Roger B Ruggeri
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Alan M Mathiowetz
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Chris Limberakis
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Groton, Connecticut, USA
| | - David Hepworth
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| | - Philip A Carpino
- Worldwide Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Cambridge, Massachusetts, USA
| |
Collapse
|
19
|
Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, Lapham K, Loria PM, Londregan AT, McClure KF, Orr STM, Patel J, Rose C, Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. ACS Med Chem Lett 2014; 5:474-9. [PMID: 24900864 DOI: 10.1021/ml400473x] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 02/18/2014] [Indexed: 01/15/2023] Open
Abstract
The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology led to the discovery of 16h. Compound 16h has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, 16h was advanced to human clinical trials.
Collapse
Affiliation(s)
- Samit K. Bhattacharya
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kim Andrews
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Ramsay Beveridge
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kimberly O. Cameron
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Chiliu Chen
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Matthew Dunn
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Dilinie Fernando
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Hua Gao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - David Hepworth
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - V. Margaret Jackson
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Vishal Khot
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jimmy Kong
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Rachel E. Kosa
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kimberly Lapham
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Paula M. Loria
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Allyn T. Londregan
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Kim F. McClure
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Suvi T. M. Orr
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jigna Patel
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Colin Rose
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - James Saenz
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Ingrid A. Stock
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Gregory Storer
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Maria VanVolkenburg
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Derek Vrieze
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Guoqiang Wang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Jun Xiao
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| | - Yingxin Zhang
- Worldwide Medicinal Chemistry, ‡Cardiovascular and
Metabolic Research Unit, §Pharmacokinetics,
Dynamics, and Metabolism, ∥Primary Pharmacology Group, and ⊥Pharmaceutical Sciences, Pfizer Global Research and Development, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
20
|
Casimiro-Garcia A, Piotrowski DW, Ambler C, Arhancet GB, Banker ME, Banks T, Boustany-Kari CM, Cai C, Chen X, Eudy R, Hepworth D, Hulford CA, Jennings SM, Loria PM, Meyers MJ, Petersen DN, Raheja NK, Sammons M, She L, Song K, Vrieze D, Wei L. Identification of (R)-6-(1-(4-Cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic Acid, a Highly Potent and Selective Nonsteroidal Mineralocorticoid Receptor Antagonist. J Med Chem 2014; 57:4273-88. [DOI: 10.1021/jm500206r] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Agustin Casimiro-Garcia
- Pfizer Worldwide Research and Development, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Catherine Ambler
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Graciela B. Arhancet
- Pfizer Worldwide Medicinal Chemistry, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Mary Ellen Banker
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tereece Banks
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Carine M. Boustany-Kari
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cuiman Cai
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xiangyang Chen
- Pfizer Worldwide Medicinal Chemistry, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Rena Eudy
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - David Hepworth
- Pfizer Worldwide Research and Development, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, United States
| | - Catherine A. Hulford
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sandra M. Jennings
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paula M. Loria
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Marvin J. Meyers
- Pfizer Worldwide Medicinal Chemistry, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Donna N. Petersen
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Neil K. Raheja
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Matthew Sammons
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Li She
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kun Song
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Derek Vrieze
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
21
|
Boehm M, Hepworth D, Loria PM, Norquay LD, Filipski KJ, Chin JE, Cameron KO, Brenner M, Bonnette P, Cabral S, Conn E, Ebner DC, Gautreau D, Hadcock J, Lee ECY, Mathiowetz AM, Morin M, Rogers L, Smith A, VanVolkenburg M, Carpino PA. Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example. ACS Med Chem Lett 2013; 4:1079-84. [PMID: 24900608 DOI: 10.1021/ml400275z] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 09/16/2013] [Indexed: 12/20/2022] Open
Abstract
Orphan G protein-coupled receptors (oGPCRs) are a class of integral membrane proteins for which endogenous ligands or transmitters have not yet been discovered. Transgenic animal technologies have uncovered potential roles for many of these oGPCRs, providing new targets for the treatment of various diseases. Understanding signaling pathways of oGPCRs and validating these receptors as potential drug targets requires the identification of chemical probe compounds to be used in place of endogenous ligands to interrogate these receptors. A novel chemical probe identification platform was created in which GPCR-focused libraries were screened against sets of oGPCR targets, with a goal of discovering fit-for-purpose chemical probes for the more druggable members of the set. Application of the platform to a set of oGPCRs resulted in the discovery of the first reported small molecule agonists for GPR39, a receptor implicated in the regulation of insulin secretion and preservation of beta cells in the pancreas. Compound 1 stimulated intracellular calcium mobilization in recombinant and native cells in a GPR39-specific manner but did not potentiate glucose-stimulated insulin secretion in human islet preparations.
Collapse
Affiliation(s)
| | | | - Paula M. Loria
- Department
of Pharmacokinetics, Dynamics and Metabolism−New Chemical Entities, Primary Pharmacology Group, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Lucy Rogers
- Department
of Pharmacokinetics, Dynamics and Metabolism−New Chemical Entities, Primary Pharmacology Group, Pfizer Worldwide Research and Development, Eastern
Point Road, Groton, Connecticut 06340, United States
| | | | | | | |
Collapse
|
22
|
Piotrowski DW, Futatsugi K, Warmus JS, Orr STM, Freeman-Cook KD, Londregan AT, Wei L, Jennings SM, Herr M, Coffey SB, Jiao W, Storer G, Hepworth D, Wang J, Lavergne SY, Chin JE, Hadcock JR, Brenner MB, Wolford AC, Janssen AM, Roush NS, Buxton J, Hinchey T, Kalgutkar AS, Sharma R, Flynn DA. Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists. ACS Med Chem Lett 2013; 4:63-8. [PMID: 24900564 DOI: 10.1021/ml300277t] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2012] [Accepted: 11/05/2012] [Indexed: 12/31/2022] Open
Abstract
Takeda G-protein-coupled receptor 5 (TGR5) represents an exciting biological target for the potential treatment of diabetes and metabolic syndrome. A new class of high-throughput screening (HTS)-derived tetrahydropyrido[4,3-d]pyrimidine amide TGR5 agonists is disclosed. We describe our effort to identify an orally available agonist suitable for assessment of systemic TGR5 agonism. This effort resulted in identification of 16, which had acceptable potency and pharmacokinetic properties to allow for in vivo assessment in dog. A key aspect of this work was the calibration of human and dog in vitro assay systems that could be linked with data from a human ex vivo peripheral blood monocyte assay that expresses receptor at endogenous levels. Potency from the human in vitro assay was also found to correlate with data from an ex vivo human whole blood assay. This calibration exercise provided confidence that 16 could be used to drive plasma exposures sufficient to test the effects of systemic activation of TGR5.
Collapse
Affiliation(s)
- David W. Piotrowski
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kentaro Futatsugi
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Joseph S. Warmus
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Suvi T. M. Orr
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | | | - Allyn T. Londregan
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sandra M. Jennings
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Michael Herr
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Steven B. Coffey
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Gregory Storer
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - David Hepworth
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jian Wang
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sophie Y. Lavergne
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Janice E. Chin
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - John R. Hadcock
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Martin B. Brenner
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Angela C. Wolford
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Ann M. Janssen
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Nicole S. Roush
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Joanne Buxton
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Terri Hinchey
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Raman Sharma
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Declan A. Flynn
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| |
Collapse
|
23
|
Futatsugi K, Bahnck KB, Brenner MB, Buxton J, Chin JE, Coffey SB, Dubins J, Flynn D, Gautreau D, Guzman-Perez A, Hadcock JR, Hepworth D, Herr M, Hinchey T, Janssen AM, Jennings SM, Jiao W, Lavergne SY, Li B, Li M, Munchhof MJ, Orr STM, Piotrowski DW, Roush NS, Sammons M, Stevens BD, Storer G, Wang J, Warmus JS, Wei L, Wolford AC. Optimization of triazole-based TGR5 agonists towards orally available agents. Med Chem Commun 2013. [DOI: 10.1039/c2md20174g] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
With the challenge of striking the balance of TGR5 potency and clearance, the screening strategy as well as medicinal chemistry strategy are discussed in this article.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Declan Flynn
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | | | | | | | - Michael Herr
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | | | | | - Wenhua Jiao
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | - Bryan Li
- Pfizer Worldwide Research and Development
- Groton
- USA
| | - Mei Li
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | | | | | | | | | | | | | - Jian Wang
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | - Liuqing Wei
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | |
Collapse
|
24
|
Bakken GA, Bell AS, Boehm M, Everett JR, Gonzales R, Hepworth D, Klug-McLeod JL, Lanfear J, Loesel J, Mathias J, Wood TP. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. J Chem Inf Model 2012; 52:2937-49. [PMID: 23062111 DOI: 10.1021/ci300372a] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
High Throughput Screening (HTS) is a successful strategy for finding hits and leads that have the opportunity to be converted into drugs. In this paper we highlight novel computational methods used to select compounds to build a new screening file at Pfizer and the analytical methods we used to assess their quality. We also introduce the novel concept of molecular redundancy to help decide on the density of compounds required in any region of chemical space in order to be confident of running successful HTS campaigns.
Collapse
Affiliation(s)
- Gregory A Bakken
- Pfizer Worldwide Research and Development, Groton, Connecticut, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ryder T, Walker GS, Goosen TC, Ruggeri RB, Conn EL, Rocke BN, Lapham K, Steppan CM, Hepworth D, Kalgutkar AS. Insights into the Novel Hydrolytic Mechanism of a Diethyl 2-Phenyl-2-(2-arylacetoxy)methyl Malonate Ester-Based Microsomal Triglyceride Transfer Protein (MTP) Inhibitor. Chem Res Toxicol 2012; 25:2138-52. [DOI: 10.1021/tx300243v] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Tim Ryder
- Pharmacokinetics, Dynamics, and Metabolism−New
Chemical Entities, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Gregory S. Walker
- Pharmacokinetics, Dynamics, and Metabolism−New
Chemical Entities, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Theunis C. Goosen
- Pharmacokinetics, Dynamics, and Metabolism−New
Chemical Entities, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Roger B. Ruggeri
- Cardiovascular Metabolic and Endocrine Diseases Medicinal
Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Edward L. Conn
- Cardiovascular Metabolic and Endocrine Diseases
Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Benjamin N. Rocke
- Cardiovascular Metabolic and Endocrine Diseases
Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kimberly Lapham
- Pharmacokinetics, Dynamics, and Metabolism−New
Chemical Entities, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Claire M. Steppan
- Pharmacokinetics, Dynamics, and Metabolism−New
Chemical Entities, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - David Hepworth
- Cardiovascular Metabolic and Endocrine Diseases Medicinal
Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Amit S. Kalgutkar
- Pharmacokinetics, Dynamics, and Metabolism−New
Chemical Entities, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
26
|
Lau WF, Withka JM, Hepworth D, Magee TV, Du YJ, Bakken GA, Miller MD, Hendsch ZS, Thanabal V, Kolodziej SA, Xing L, Hu Q, Narasimhan LS, Love R, Charlton ME, Hughes S, van Hoorn WP, Mills JE. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. J Comput Aided Mol Des 2011; 25:621-36. [PMID: 21604056 DOI: 10.1007/s10822-011-9434-0] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Accepted: 05/06/2011] [Indexed: 11/26/2022]
Abstract
Fragment Based Drug Discovery (FBDD) continues to advance as an efficient and alternative screening paradigm for the identification and optimization of novel chemical matter. To enable FBDD across a wide range of pharmaceutical targets, a fragment screening library is required to be chemically diverse and synthetically expandable to enable critical decision making for chemical follow-up and assessing new target druggability. In this manuscript, the Pfizer fragment library design strategy which utilized multiple and orthogonal metrics to incorporate structure, pharmacophore and pharmacological space diversity is described. Appropriate measures of molecular complexity were also employed to maximize the probability of detection of fragment hits using a variety of biophysical and biochemical screening methods. In addition, structural integrity, purity, solubility, fragment and analog availability as well as cost were important considerations in the selection process. Preliminary analysis of primary screening results for 13 targets using NMR Saturation Transfer Difference (STD) indicates the identification of uM-mM hits and the uniqueness of hits at weak binding affinities for these targets.
Collapse
Affiliation(s)
- Wan F Lau
- Pfizer Global Research and Development (PGRD), Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Attkins N, Betts A, Hepworth D, Heatherington AC. Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. Xenobiotica 2010; 40:730-42. [DOI: 10.3109/00498254.2010.514961] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
28
|
Lansdell MI, Hepworth D, Calabrese A, Brown AD, Blagg J, Burring DJ, Wilson P, Fradet D, Brown TB, Quinton F, Mistry N, Tang K, Mount N, Stacey P, Edmunds N, Adams C, Gaboardi S, Neal-Morgan S, Wayman C, Cole S, Phipps J, Lewis M, Verrier H, Gillon V, Feeder N, Heatherington A, Sultana S, Haughie S, Martin SW, Sudworth M, Tweedy S. Discovery of a Selective Small-Molecule Melanocortin-4 Receptor Agonist with Efficacy in a Pilot Study of Sexual Dysfunction in Humans. J Med Chem 2010; 53:3183-97. [DOI: 10.1021/jm9017866] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Mark I. Lansdell
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - David Hepworth
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Andrew Calabrese
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Alan D. Brown
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Julian Blagg
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Denise J. Burring
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Peter Wilson
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - David Fradet
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - T. Bruce Brown
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Faye Quinton
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Neela Mistry
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Kim Tang
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Natalie Mount
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Peter Stacey
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Nick Edmunds
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Cathryn Adams
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Samantha Gaboardi
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Stevie Neal-Morgan
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Chris Wayman
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Susan Cole
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Joanne Phipps
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Mark Lewis
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Hugh Verrier
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Val Gillon
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Neil Feeder
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Anne Heatherington
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Stefan Sultana
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Scott Haughie
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Steven W. Martin
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Maria Sudworth
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| | - Sarah Tweedy
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K
| |
Collapse
|
29
|
Davies SG, Goodwin CJ, Hepworth D, Roberts PM, Thomson JE. On the Origins of Diastereoselectivity in the Alkylation of Enolates Derived from N-1-(1′-Naphthyl)ethyl-O-tert-butylhydroxamates: Chiral Weinreb Amide Equivalents. J Org Chem 2010; 75:1214-27. [DOI: 10.1021/jo902499s] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Stephen G. Davies
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom
| | - Christopher J. Goodwin
- AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom
| | - David Hepworth
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom
| | - Paul M. Roberts
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom
| | - James E. Thomson
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, United Kingdom
| |
Collapse
|
30
|
Chernega AN, Davies SG, Goodwin CJ, Hepworth D, Kurosawa W, Roberts PM, Thomson JE. The Chiral Auxiliary N-1-(1′-Naphthyl)ethyl-O-tert-butylhydroxylamine: A Chiral Weinreb Amide Equivalent. Org Lett 2009; 11:3254-7. [DOI: 10.1021/ol901174t] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Alexander N. Chernega
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| | - Stephen G. Davies
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| | - Christopher J. Goodwin
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| | - David Hepworth
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| | - Wataru Kurosawa
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| | - Paul M. Roberts
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| | - James E. Thomson
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K., and AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leicestershire LE11 5RH, U.K
| |
Collapse
|
31
|
Lansdell MI, Burring DJ, Hepworth D, Strawbridge M, Graham E, Guyot T, Betson MS, Hart JD. Design and synthesis of fluorescent SGLT2 inhibitors. Bioorg Med Chem Lett 2008; 18:4944-7. [DOI: 10.1016/j.bmcl.2008.08.036] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2008] [Revised: 08/11/2008] [Accepted: 08/12/2008] [Indexed: 11/30/2022]
|
32
|
Middleton DS, Andrews M, Glossop P, Gymer G, Hepworth D, Jessiman A, Johnson PS, MacKenny M, Stobie A, Tang K, Morgan P, Jones B. Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines. Bioorg Med Chem Lett 2008; 18:5303-6. [PMID: 18782666 DOI: 10.1016/j.bmcl.2008.08.040] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2008] [Revised: 08/11/2008] [Accepted: 08/12/2008] [Indexed: 11/30/2022]
Abstract
A series of thio-alkyl containing diphenylethers were designed and evaluated, as a strategy to competitively direct metabolism away from unwanted amine N-demethylation and deliver a pharmacologically inactive S-oxide metabolite. Overall, sulfonamide 20 was found to possess the best balance of target pharmacology, pharmacokinetics and metabolism profile.
Collapse
Affiliation(s)
- Donald S Middleton
- Department of Discovery Chemistry (B500, IPC 324), Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Middleton DS, Andrews M, Glossop P, Gymer G, Hepworth D, Jessiman A, Johnson PS, MacKenny M, Pitcher MJ, Rooker T, Stobie A, Tang K, Morgan P. Designing rapid onset selective serotonin re-uptake inhibitors. 2: Structure–activity relationships of substituted (aryl)benzylamines. Bioorg Med Chem Lett 2008; 18:4018-21. [DOI: 10.1016/j.bmcl.2008.06.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2008] [Revised: 06/02/2008] [Accepted: 06/02/2008] [Indexed: 10/22/2022]
|
34
|
Moss TA, Alba A, Hepworth D, Dixon DJ. Efficient base catalyzed alkylation reactions with aziridine electrophiles. Chem Commun (Camb) 2008:2474-6. [DOI: 10.1039/b802447b] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
35
|
Ulvskov P, Wium H, Bruce D, Jørgensen B, Qvist KB, Skjøt M, Hepworth D, Borkhardt B, Sørensen SO. Biophysical consequences of remodeling the neutral side chains of rhamnogalacturonan I in tubers of transgenic potatoes. Planta 2005; 220:609-20. [PMID: 15517357 DOI: 10.1007/s00425-004-1373-8] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2004] [Accepted: 08/02/2004] [Indexed: 05/18/2023]
Abstract
Two lines of transgenic potato (Solanum tuberosum L.) plants modified in their cell wall structure were characterized and compared to wild type with regard to biomechanical properties in order to assign functional roles to the particular cell wall polysaccharides that were targeted by the genetic changes. The targeted polymer was rhamnogalacturonan I (RG-I), a complex pectic polysaccharide comprised of mainly neutral oligosaccharide side chains attached to a backbone of alternating rhamnosyl and galacturonosyl units. Tuber rhamnogalacturonan I molecules from the two transformed lines are reduced in linear galactans and branched arabinans, respectively. The transformed tuber tissues were found to be more brittle when subjected to uniaxial compression and the side-chain truncation was found to be correlated with the physical properties of the tissue. Interpretation of the force-deflection curves was aided by a mathematical model that describes the contribution of the cellulose microfibrils, and the results lead to the proposition that the pectic matrix plays a role in transmitting stresses to the load-bearing cellulose microfibrils and that even small changes to the rheological properties of the matrix have consequences for the biophysical properties of the wall.
Collapse
Affiliation(s)
- Peter Ulvskov
- Biotechnology Group, Danish Institute of Agricultural Sciences, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Nicolaou KC, Fylaktakidou KC, Monenschein H, Li Y, Weyershausen B, Mitchell HJ, Wei HX, Guntupalli P, Hepworth D, Sugita K. Total Synthesis of Apoptolidin: Construction of Enantiomerically Pure Fragments. J Am Chem Soc 2003; 125:15433-42. [PMID: 14664589 DOI: 10.1021/ja0304953] [Citation(s) in RCA: 103] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A general strategy for the total synthesis of the antitumor agent apoptolidin (1) is proposed, and the chemical synthesis of the defined key building blocks (4, 5, 6, 8, and 9) in their enantiomerically pure forms is described. The projected total synthesis calls for a dithiane coupling reaction to construct the C(20)-C(21) bond, a Stille coupling reaction to form the C(11)-C(12) bond, and a Yamaguchi macrolactonization to assemble the macrolide ring, as well as two glycosidation reactions to fuse the carbohydrate units onto the molecule. First and second generation syntheses to the required fragments for apoptolidin (1) are described.
Collapse
Affiliation(s)
- K C Nicolaou
- Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kuperus W, Hummel K, Roney J, Szakacs N, Macmillan C, Wickenheiser RA, Hepworth D, Hrycak T, Fenske B, De Gouffe M, Carroll C, Reader L, Nicholson M, Sanders T, Lett C. Crime Scene Links Through DNA Evidence: The Practical Experience from Saskatchewan Casework. Canadian Society of Forensic Science Journal 2003. [DOI: 10.1080/00085030.2003.10757553] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Nicolaou KC, Hepworth D, King NP, Finlay MR, Scarpelli R, Pereira MM, Bollbuck B, Bigot A, Werschkun B, Winssinger N. Total synthesis of 16-desmethylepothilone B, epothilone B10, epothilone F, and related side chain modified epothilone B analogues. Chemistry 2000; 6:2783-800. [PMID: 10985727 DOI: 10.1002/1521-3765(20000804)6:15<2783::aid-chem2783>3.0.co;2-b] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The macrolactonization-based strategy for the total synthesis of epothilones has been streamlined and improved to a high level of efficiency and stereoselectivity. This strategy has been applied to the construction of vinyl iodide 19 which served as a common intermediate for the synthesis of a series of natural and designed epothilones including an epothilone B10 (3), epothilone F (5), 16-desmethylepothilone B (14), pyridine epothilones 57a-57g, dimeric epothilones 59 and 61, and benzenoid epothilones 63a-63g.
Collapse
Affiliation(s)
- K C Nicolaou
- Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Nicolaou KC, King NP, Finlay MR, He Y, Roschangar F, Vourloumis D, Vallberg H, Sarabia F, Ninkovic S, Hepworth D. Total synthesis of epothilone E and related side-chain modified analogues via a Stille coupling based strategy. Bioorg Med Chem 1999; 7:665-97. [PMID: 10400321 DOI: 10.1016/s0968-0896(98)00153-9] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
A Stille coupling strategy has been utilized to complete a total synthesis of epothilone E from vinyl iodide 7 and thiazole-stannane 8h. The central core fragment 7 and its trans-isomer 11 were prepared from triene 15 using ring-closing metathesis (RCM), and were subsequently coupled to a variety of alternative stannanes to provide a library of epothilone analogues 18a-o and 19a-o. The Stille coupling approach was then used to prepare epothilone B analogues from the key macrolactone intermediate 24 which was itself synthesized by a macrolactonization based strategy.
Collapse
Affiliation(s)
- K C Nicolaou
- Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D, Nicolaou KC. The Chemistry and Biology of Alkannin, Shikonin, and Related Naphthazarin Natural Products. Angew Chem Int Ed Engl 1999; 38:270-301. [PMID: 29711637 DOI: 10.1002/(sici)1521-3773(19990201)38:3<270::aid-anie270>3.0.co;2-0] [Citation(s) in RCA: 387] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/1997] [Indexed: 11/08/2022]
Abstract
Wound healing properties of plant extracts that contain the naphthoquinone natural products alkannin (1) and shikonin (2) have been known for many centuries. More recently, the biological properties of 1, 2, and related derivatives have been demonstrated experimentally, and their production both by cell cultures and chemical synthesis has been studied extensively.
Collapse
Affiliation(s)
- Vassilios P Papageorgiou
- Organic Chemistry Laboratory, Chemical Engineering Department, Aristotle University of Thessaloniki, 54006 Thessaloniki (Greece), Fax: (+30) 31-996252
| | - Andreana N Assimopoulou
- Organic Chemistry Laboratory, Chemical Engineering Department, Aristotle University of Thessaloniki, 54006 Thessaloniki (Greece), Fax: (+30) 31-996252
| | - Elias A Couladouros
- Chemical Laboratories, Agricultural University of Athens, Iera Odos 75, 118.55 (Greece) (and) Organic and Bio-organic Laboratories, NCSR "DEMOKRITOS", 153.10 Ag. Paraskevi Attikis, POB 60228 (Greece)
| | - David Hepworth
- Department of Chemistry and, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037 (USA), Fax: (+1) 619-784-2469 (and) Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093 (USA)
| | - K C Nicolaou
- Department of Chemistry and, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037 (USA), Fax: (+1) 619-784-2469 (and) Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093 (USA)
| |
Collapse
|
41
|
|
42
|
Nicolaou KC, Hepworth D, Finlay MRV, Paul King N, Werschkun B, Bigot A. Synthesis of 16-desmethylepothilone B: improved methodology for the rapid, highly selective and convergent construction of epothilone B and analogues. Chem Commun (Camb) 1999. [DOI: 10.1039/a809954e] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
43
|
|
44
|
|
45
|
Davies SG, Furtado OMLR, Hepworth D, Loveridge T. α-Stereoselective Tandem Additions to (ortho-Methoxystyrene) Chromium Tricarbonyl. Synlett 1995. [DOI: 10.1055/s-1995-4865] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
46
|
|
47
|
Hepworth D. The decision process of the mental health review tribunal--I. Review of literature and research. Med Sci Law 1983; 23:131-141. [PMID: 6865700 DOI: 10.1177/002580248302300215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
48
|
|